Literature DB >> 12023894

The terminal six amino-acids of the carboxy cytoplasmic tail of CD36 contain a functional domain implicated in the binding and capture of oxidized low-density lipoprotein.

Eric Malaud1, Delphine Hourton, Louise Marie Giroux, Ewa Ninio, Robin Buckland, John L McGregor.   

Abstract

CD36, a major adhesion molecule expressed by monocytes/macrophages, plays a key role in the binding and internalization of oxidized low-density lipoprotein (OxLDL). This adhesion molecule, a member of an important scavenger receptor family, contains a very short C-terminal cytoplasmic tail that is known to induce intracellular signalling events. However, the domains on the cytoplasmic tail involved in such signal transduction are unknown. In this study, we have investigated the functional components of the cytoplasmic tail by site-directed mutagenesis coupled with functional OxLDL and monoclonal antibody (mAb) binding studies. Seven truncated or punctual CD36 constructs, localized in the cytoplasmic tail, were produced by site-directed mutagenesis. Each construct was stably expressed in HEK293 cells. We used a quantitative and a qualitative method, labelling OxLDL with either iodine or rhodamine, to determine the functional importance of the cytoplasmic domains in OxLDL internalization. Results indicate that: (1) a deletion of the last amino-acid (construct K472STOP) significantly reduces, compared with wild-type, the binding, internalization and degradation of OxLDL; (2) truncation of the last six amino-acids (construct R467STOP) significantly reduces OxLDL binding; (3) the above two constructs (K472STOP and R467STOP) showed a reduced rate of OxLDL internalization compared with wild-type; (4) the binding and rate of internalization of an anti-CD36 monoclonal antibody (10/5) was not affected by the above mentioned mutants (K472STOP and R467STOP), compared with wild-type. This study shows, for the first time, a specific site on the CD36 cytoplasmic tail that is critical for the binding, endocytosis and targeting of OxLDL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023894      PMCID: PMC1222596          DOI: 10.1042/BJ20011373

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

1.  Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site.

Authors:  A C Nicholson; S Frieda; A Pearce; R L Silverstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-02       Impact factor: 8.311

2.  Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation.

Authors:  H Y Huh; S F Pearce; L M Yesner; J L Schindler; R L Silverstein
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

3.  CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails.

Authors:  N Tao; S J Wagner; D M Lublin
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

4.  Characterization of two vaccinia CD36 recombinant-virus-generated monoclonal antibodies (10/5, 13/10): effects on malarial cytoadherence and platelet functions.

Authors:  L Daviet; A G Craig; L McGregor; R Pinches; T F Wild; A R Berendt; C I Newbold; J L McGregor
Journal:  Eur J Biochem       Date:  1997-01-15

5.  Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils.

Authors:  M D Navazo; L Daviet; J Savill; Y Ren; L L Leung; J L McGregor
Journal:  J Biol Chem       Date:  1996-06-28       Impact factor: 5.157

6.  Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL).

Authors:  M D Puente Navazo; L Daviet; E Ninio; J L McGregor
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

7.  Thrombospondin induces dimerization of membrane-bound, but not soluble CD36.

Authors:  L Daviet; E Malvoisin; T F Wild; J L McGregor
Journal:  Thromb Haemost       Date:  1997-08       Impact factor: 5.249

8.  The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha.

Authors:  R H Lipsky; D M Eckert; Y Tang; C F Ockenhouse
Journal:  Recept Signal Transduct       Date:  1997

9.  Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet.

Authors:  D E Greenwalt; S H Scheck; T Rhinehart-Jones
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport.

Authors:  A Ibrahimi; Z Sfeir; H Magharaie; E Z Amri; P Grimaldi; N A Abumrad
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  4 in total

Review 1.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

2.  CD36 signaling inhibits the translation of heat shock protein 70 induced by oxidized low density lipoprotein through activation of peroxisome proliferators-activated receptor gamma.

Authors:  Kyoung Jin Lee; Eun Soo Ha; Min Kyoung Kim; Sang Hoon Lee; Jae Sung Suh; Sun Hee Lee; Kyeong Han Park; Jeong Hyun Park; Dae Joong Kim; Dongmin Kang; Byung Chul Kim; Dooil Jeoung; Young Kyoun Kim; Ho Dirk Kim; Jang Hee Hahn
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

3.  Plasma Membrane Localization of CD36 Requires Vimentin Phosphorylation; A Mechanism by Which Macrophage Vimentin Promotes Atherosclerosis.

Authors:  Seo Yeon Kim; Se-Jin Jeong; Ji-Hae Park; Wonkyoung Cho; Young-Ho Ahn; Youn-Hee Choi; Goo Taeg Oh; Roy L Silverstein; Young Mi Park
Journal:  Front Cardiovasc Med       Date:  2022-05-18

4.  CD36-specific antibodies block release of HIV-1 from infected primary macrophages and its transmission to T cells.

Authors:  Stefano Berre; Raphaël Gaudin; Bruna Cunha de Alencar; Marion Desdouits; Mélanie Chabaud; Nadia Naffakh; Marc Rabaza-Gairi; François-Xavier Gobert; Mabel Jouve; Philippe Benaroch
Journal:  J Exp Med       Date:  2013-10-21       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.